Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2− breast cancerAnthony Elias, Jennifer K. Richer, Vida Alami et al.|npj Breast Cancer|2024Cited by 9
Abstract PS18-07: Differential odds of response in ILC versus IDC correlate with changes in the TIME in a phase II trial of pre-operative fulvestrant with or without enzalutamideJennifer K. Richer, Dexiang Gao, Anthony Elias et al.|Clinical Cancer Research|2025Cited by 0